<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The Glycemic Effect in <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo>: <z:chebi fb="0" ids="3441">Carvedilol</z:chebi>-<z:chebi fb="0" ids="6904">Metoprolol</z:chebi> Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> treated with renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) blockade and found differences in metabolic outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The <z:mp ids='MP_0002055'>Diabetes</z:mp> Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of <z:mp ids='MP_0002055'>diabetes</z:mp>-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5) </plain></SENT>
<SENT sid="3" pm="."><plain>The DSC assessed symptoms in eight domains: psychology (<z:mp ids='MP_0002899'>fatigue</z:mp>), psychology (cognitive), <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (pain), <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (sensory), cardiology, ophthalmology, <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Comparison of the mean change in self-reported <z:mp ids='MP_0002055'>diabetes</z:mp>-related symptoms indicated a significant treatment difference favouring <z:chebi fb="0" ids="3441">carvedilol</z:chebi> over <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> in overall symptom score (-0.08; 95% CI -0.15, -0.01; p = 0.02) and in the domains for <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> symptoms (-0.12; 95% CI -0.23, -0.02; p = 0.02) and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> symptoms (-0.16; 95% CI -0.27, -0.05; p = 0.005) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="3441">Carvedilol</z:chebi> resulted in fewer perceived <z:mp ids='MP_0002055'>diabetes</z:mp>-related symptoms in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="3441">Carvedilol</z:chebi> resulted in a lower perceived burden of <z:mp ids='MP_0002055'>diabetes</z:mp>-related symptoms in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The addition of a well-tolerated beta-blocker to <z:mp ids='MP_0011356'>RAS</z:mp> blockade may improve <z:hpo ids='HP_0000822'>hypertension</z:hpo> treatment and quality of life in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>